<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639986</url>
  </required_header>
  <id_info>
    <org_study_id>EVER-132-002</org_study_id>
    <nct_id>NCT04639986</nct_id>
  </id_info>
  <brief_title>Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- MBC</brief_title>
  <official_title>A Phase 3 Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With HR+/ HER2- Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Everest Medicines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Everest Medicines</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and&#xD;
      safety of sacituzumab govitecan versus TPC in subjects with metastatic or locally recurrent&#xD;
      inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy&#xD;
      regimens for metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 330 eligible subjects will be randomly allocated to one of the following 2&#xD;
      treatment arms in a 1:1 ratio:&#xD;
&#xD;
      Investigational Arm:&#xD;
&#xD;
      Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day&#xD;
      cycle).&#xD;
&#xD;
      Control Arm:&#xD;
&#xD;
      Recommended doses and schedules as per NCCN guidelines (with dose modifications if too&#xD;
      toxic).&#xD;
&#xD;
      Eribulin; Capecitabine; Gemcitabine; Vinorelbine Subjects will be treated until PD as judged&#xD;
      by local investigator review, development of unacceptable toxicity, or withdrawal of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>within approximately 3 years</time_frame>
    <description>PFS measured from the date of randomization until the date of PD or death, whichever occurs earlier. Disease progression will be determined according to RECIST v 1.1 by an IRC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival [OS]</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as from the date of randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate [ORR] by IRC</measure>
    <time_frame>3 years</time_frame>
    <description>Objective response includes CR and PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response [DOR] by IRC</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as from the date of first onset of tumor response (CR or PR) to PD or death, whichever occurs earlier.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recommended doses and schedules as per package insert depending on region.&#xD;
Eribulin (1.4 mg/m2 of eribulin mesylate or 1.23 mg/m2 of eribulin IV on Days 1 and 8 of a 21-day cycle)&#xD;
Capecitabine (1000 to 1250 mg/m2 PO twice daily on Days 1 to 14 of a 21-day cycle)&#xD;
Gemcitabine (800 to 1200 mg/m2 IV on Days 1, 8, and 15 of a 28-day cycle)&#xD;
Vinorelbine (25 mg/m2 IV on Day 1 weekly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacituzumab govitecan (IMMU-132)</intervention_name>
    <description>Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Trodelvy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin Mesylate Injection</intervention_name>
    <description>Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine Oral Product</intervention_name>
    <description>Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Injection</intervention_name>
    <description>Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine injection</intervention_name>
    <description>Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male subjects aged ≥18 years at the time of signing the informed consent&#xD;
             form&#xD;
&#xD;
          -  Documented evidence of hormone receptor-positive HER2-negative (HR+/HER2-) MBC&#xD;
             confirmed&#xD;
&#xD;
          -  Refractory to or relapsed after at least 2, and no more than 4, prior systemic&#xD;
             chemotherapy regimens for MBC&#xD;
&#xD;
          -  Should have been previously treated with at least 1 taxane in any setting, at least 1&#xD;
             prior anticancer hormonal treatment in any setting&#xD;
&#xD;
          -  Eligible for one of the chemotherapy options listed in the TPC arm&#xD;
&#xD;
          -  Documented radiographic disease progression after the most recent therapy&#xD;
&#xD;
          -  Measurable disease by CT or MRI in accordance with RECIST v 1.1, bone-only disease is&#xD;
             not measurable and is not permitted.&#xD;
&#xD;
          -  Adequate bone marrow function, hepatic and renal function&#xD;
&#xD;
          -  Females must not be lactating or pregnant at Screening or Baseline (as documented by a&#xD;
             negative beta human chorionic gonadotropin [ß-hCG]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with Topoisomerase 1 Inhibitors as a free form or as other&#xD;
             formulations&#xD;
&#xD;
          -  Subjects who have known brain metastases.&#xD;
&#xD;
          -  Have an active second malignancy within 3 years prior to providing informed consent&#xD;
&#xD;
          -  Subjects with active hepatitis B virus (HBV), or hepatitis C virus infection&#xD;
             (measurable viral RNA load with polymerase chain reaction).&#xD;
&#xD;
          -  Active serious infection requiring systemic antibiotic use within 7 days before C1D1.&#xD;
&#xD;
          -  Patients with a history of an anaphylactic reaction to irinotecan.&#xD;
&#xD;
          -  Other concurrent medical or psychiatric conditions that, in the Investigator's&#xD;
             opinion, may be likely to confound study interpretation or prevent completion of study&#xD;
             procedures and follow-up examinations.&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to either of the study treatments or any of the&#xD;
             excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Everest Medicines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingjun Shi</last_name>
    <phone>8613916513539</phone>
    <email>yingjun.shi@everestmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee Hyun Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Hwa Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Hyuck Im</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seoc kAh Im</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Medical Foundation Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator Everest</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator Everest</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Alberti S, Trerotola M, Vacca G, et al. TROP2 is a major determinant of growth and metastatic spreading of human cancer. J Clin Oncol. 2007;25:Abst 10510.</citation>
  </reference>
  <reference>
    <citation>Bardia A, Diamond JR, Vahdat LT, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J Clin Oncol. 2018;36(15 suppl):1004</citation>
  </reference>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. doi: 10.1158/1078-0432.CCR-10-2939. Epub 2011 Mar 3.</citation>
    <PMID>21372224</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.</citation>
    <PMID>25915780</PMID>
  </reference>
  <reference>
    <citation>Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.</citation>
    <PMID>26596672</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014 Jun;15(7):e279-89. doi: 10.1016/S1470-2045(13)70567-9. Review.</citation>
    <PMID>24872111</PMID>
  </reference>
  <reference>
    <citation>Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009 Aug;24(8):875-84. doi: 10.1007/s00384-009-0725-z. Epub 2009 May 7.</citation>
    <PMID>19421758</PMID>
  </reference>
  <reference>
    <citation>Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 8;6(26):22496-512. Erratum in: Oncotarget. 2020 Mar 10;11(10):942.</citation>
    <PMID>26101915</PMID>
  </reference>
  <reference>
    <citation>Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009 Oct 1;15(19):6052-61. doi: 10.1158/1078-0432.CCR-09-0586. Epub 2009 Sep 29.</citation>
    <PMID>19789330</PMID>
  </reference>
  <reference>
    <citation>Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015 Jan 21;7:37-46. doi: 10.2147/CMAR.S72592. eCollection 2015. Review.</citation>
    <PMID>25653556</PMID>
  </reference>
  <reference>
    <citation>Investigator's Brochure: Sacituzumab Govitecan (Company Code: IMMU-132) (hRS7-SN38; Anti-Trop2-Drug Conjugate) for Patients with Epithelial Cancers, Version 7, 17 June 2019.</citation>
  </reference>
  <reference>
    <citation>Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013 Jul;76(1):48-57. doi: 10.1111/bcp.12040. Review.</citation>
    <PMID>23167578</PMID>
  </reference>
  <reference>
    <citation>Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567-74.</citation>
    <PMID>7595708</PMID>
  </reference>
  <reference>
    <citation>Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, Youn HJ; Korean Breast Cancer Society. Basic Findings Regarding Breast Cancer in Korea in 2015: Data from a Breast Cancer Registry. J Breast Cancer. 2018 Mar;21(1):1-10. doi: 10.4048/jbc.2018.21.1.1. Epub 2018 Mar 23. Review. Erratum in: J Breast Cancer. 2019 Feb 19;22(1):153.</citation>
    <PMID>29628978</PMID>
  </reference>
  <reference>
    <citation>Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.</citation>
    <PMID>25605862</PMID>
  </reference>
  <reference>
    <citation>Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC, Yen Y. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. J Formos Med Assoc. 2020 Dec;119(12):1731-1741. doi: 10.1016/j.jfma.2019.08.023. Epub 2019 Sep 12. Review.</citation>
    <PMID>31522970</PMID>
  </reference>
  <reference>
    <citation>Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001 Aug;7(8):2182-94. Review.</citation>
    <PMID>11489791</PMID>
  </reference>
  <reference>
    <citation>Moon SJ, Tat F, Sheerin A, et al. Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy. Proc Amer Assoc Cancer Res. 2010,51:591-592 Abstract 2349, doi: 10.1158/1538 7445.</citation>
  </reference>
  <reference>
    <citation>Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.</citation>
    <PMID>28558150</PMID>
  </reference>
  <reference>
    <citation>Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010 Jun;121(2):261-71. doi: 10.1007/s10549-010-0824-0. Epub 2010 Mar 13. Review.</citation>
    <PMID>20229176</PMID>
  </reference>
  <reference>
    <citation>Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009 May 15;169(10):1251-9. doi: 10.1093/aje/kwp036. Epub 2009 Mar 24.</citation>
    <PMID>19318616</PMID>
  </reference>
  <reference>
    <citation>Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.</citation>
    <PMID>26106073</PMID>
  </reference>
  <reference>
    <citation>Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007 Sep;12(9):1070-83. Review.</citation>
    <PMID>17914077</PMID>
  </reference>
  <reference>
    <citation>Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, Adams D, Jiang Z, Languino LR. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res. 2010 Mar 15;2(2):135-44.</citation>
    <PMID>20407603</PMID>
  </reference>
  <reference>
    <citation>Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer (Auckl). 2016 Jun 28;10:77-84. doi: 10.4137/BCBCR.S39615. eCollection 2016.</citation>
    <PMID>27398025</PMID>
  </reference>
  <reference>
    <citation>Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019 May;112:57-65. doi: 10.1016/j.ejca.2019.02.002. Epub 2019 Mar 29.</citation>
    <PMID>30928806</PMID>
  </reference>
  <reference>
    <citation>Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW, He J. [Report of cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005. Chinese.</citation>
    <PMID>30678413</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sacituzumab govitecan</keyword>
  <keyword>IMMU-132</keyword>
  <keyword>Unresectable or Metastatic Breast Cancer</keyword>
  <keyword>hormonal receptor</keyword>
  <keyword>HR positive</keyword>
  <keyword>Anti-TROP2</keyword>
  <keyword>Human epidermal growth factor receptor 2 (HER2) Negative</keyword>
  <keyword>Antibody Drug Conjugate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

